MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript

So as you know, or for those of you who don’t know, bot/bal has generated really remarkable activity in cold tumors and more than 900 patients studied nine different tumor types that are that have been previously unresponsive to immune therapies are actually responding to bot/bal and it opens up an enormous opportunity for patients with these diseases that have previously gone – unable to be treated effectively. In metastatic colorectal cancer, MSS CRC now, this is the largest population of colorectal cancers. It represents about 95% of the population of patients with colorectal cancer and it’s growing. It will represent the largest killer of men under 50 shortly. And this has been widely published and available in both the scientific literature, as well as in the late literature.

What we have observed with the activity in nearly 400 patients treated with MSS CRC is, bot/bal standard of care therapies bring anywhere from 2% to 3% tumor shrinkage. And we’re seeing more than a tenfold improvement of tumor shrinkage in that indication when patients are treated with bot/bal. And while we have not yet achieved a median survival in this study in the in the randomized phase 2 study, We have observed a more than doubling beyond two years of survival, which is really as far as we can tell unprecedented in this indication. The one area where we believe we can improve upon the activity of bot/bal, we do see that bot/bal is active in generating a survival benefit in patients with metastatic disease to deliver. But not as – it’s not as active in shrinking tumors within the liver.

Now what we know about iNKTs is they actually home to the liver disease and we have observed in our own hands that iNKTs can modulate disease in the liver. So we believe that in addition to the survival benefit that bot/bal can bring to patients with MSS CRC with liver match, we think that the addition of iNKTs may actually contribute to the reduction of disease burden in the liver and may actually expand survival benefit even further beyond what bot/bal could do alone. We will be testing that in an externally funded trial with a KOL that we will announce very shortly as soon as we launch that program, which is going to be happening in the first half of this year.

Mayank Mamtani : Thank you, Jen. Looking forward to those updates.

Jennifer Buell : Thank you very much Mayank.

Operator: Thank you. And that does conclude the question and answer session. I would like to turn the call back over to Dr. Jen Buell for closing remarks.

Jennifer Buell: Thank you very much operator. Thank you all for your questions and your participation today. We really appreciate your continued support and look forward to speaking with you again soon. Thank you.

Operator: Thank you, everyone. That does conclude today’s presentation. Thank you for your participation today. You may now disconnect.